Search the Newsreel

Gildan Activewear, Inc. $GIL Shares Sold by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund reduced its stake in Gildan Activewear, Inc. (NYSE:GIL) by 72.8% in the first quarter, selling 145,770 shares. Despite this, institutional investors collectively own 82.83% of the company. Gildan reported strong Q2 earnings, exceeding analyst expectations, and announced …

Scotia Forecasts Strong Price Appreciation for Gildan Activewear (NYSE:GIL) Stock

Gildan Activewear (NYSE:GIL) Trading 7% Higher After Strong Earnings

Gildan Activewear incorporates 'durable' tariff tailwind into FY26 profit outlook (GIL:NYSE)

Canada's Gildan Activewear's Q1 revenue surges 64% on HanesBrands deal

Canadian apparel manufacturer Gildan Activewear Inc. reported a 63.8% year-on-year surge in first-quarter net sales, reaching $1.17 billion, primarily due to the full consolidation of HanesBrands. Despite the revenue growth, the company posted a net loss of $55.1 million from continuing operations, attributed to …

Gildan Activewear, Inc. Stock 12‑Month Price Target Raised to $79.64, Implies 55% Upside

Gildan Activewear, Inc. (GIL) has seen its average 12-month stock price target raised to $79.64 from $79, according to estimates from 11 analysts. This updated target suggests a potential upside of approximately 55% based on the July 29 closing price. The consensus rating for …

Gildan Activewear, Inc. (NYSE:GIL) Announces Quarterly Dividend of $0.25

Gildan Activewear, Inc. (NYSE:GIL) declared a quarterly dividend of $0.249 per share, payable on September 14th to shareholders of record as of August 20th. The company reported strong quarterly earnings of $1.28 per share, surpassing analyst estimates, and saw revenue increase by 72.3% year-over-year. …

Gildan Activewear Inc (GIL) (Q2 2026) Earnings Call Highlights: Strong Earnings Beat and Raised ...

This article first appeared on GuruFocus. Release Date: July 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Strong Q2 2026 results with net sales from continuing operations up 72% year-over-year to $1.58 …

Gilead Sciences Inc. stock outperforms competitors despite losses on the day

Gilead Sciences Inc. (GILD) saw its stock shed 1.09% to $131.28 on Thursday, marking its second consecutive day of losses. This occurred despite a generally favorable trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both experiencing …

Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

The upcoming report from Gilead Sciences (GILD) is expected to reveal quarterly loss of -$7.07 per share, indicating a decline of 451.7% compared to the year-ago period. Analysts forecast revenues of $7.37 billion, representing an increase of 4% year over year. The consensus EPS …

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this HIV and hepatitis C drugmaker have …

Gildan reports Q2 loss of US$50M, announces sale of HanesBrands Australia

Gildan Activewear Inc. reported a Q2 loss of US$50 million and announced the sale of HanesBrands' Australian division for approximately US$490 million. Despite expecting a US$220 million refund from overturned U.S. tariffs, the company stated it is unlikely to cut prices, opting instead to …

Gildan Activewear Q2 Net Earnings Jumps 32% YoY

Gildan Activewear (GIL.TO) Thursday reported Q2 net earnings, stripped of most one-time items, jumpe PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

Gildan Activewear (NYSE: GIL) grows to $1.58B Q2 revenue but books loss

Gildan Activewear reported a Q2 2026 net loss of $50 million, despite net sales increasing by 72.3% year-over-year to $1.58 billion, primarily due to the HanesBrands acquisition. The loss was primarily driven by a $140.4 million loss from discontinued operations, including a $153 million …

Gildan expects to receive $220-million tariff refund, raises 2026 outlook despite quarterly loss

Gildan Activewear Inc. expects a $220 million tariff refund from overturned U.S. President Donald Trump-era tariffs, which it plans to reinvest in the business rather than passing on to customers. Despite reporting a second-quarter loss of US$50 million and selling HanesBrands' Australian division for …

Gildan Activewear (GIL) Tops Q2 Earnings Estimates

Gildan Activewear (GIL) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.97 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Gilead Stock: Buy The Distortion Before Q2 Clears It Up (NASDAQ:GILD)

Gilead Sciences (GILD) is presented as a strong buy, despite a temporary $11.5 billion impairment, research, and development (IPR&D) charge that may negatively impact short-term optics but not the company's long-term fundamentals. The article highlights GILD's growing HIV franchise, its emerging oncology pipeline driven …

Turtle Creek Asset Management Inc. Sells 269,350 Shares of Gildan Activewear, Inc. $GIL

Turtle Creek Asset Management Inc. reduced its stake in Gildan Activewear (NYSE:GIL) by 24.8% in the first quarter, selling 269,350 shares, but still retains a significant holding worth approximately $45.5 million. Despite Gildan Activewear's stock trading down 1.2% at $51.10, the company recently beat …

Earnings Flash (GIL) Gildan Activewear Inc. Posts Q2 Adjusted EPS $1.28 per Share, vs. FactSet Est of $1.12

Gildan Activewear Inc. (GIL) announced adjusted earnings per share of $1.28 for Q2, surpassing the FactSet estimate of $1.12. The company's fiscal Q2 adjusted earnings and net sales rose, leading them to raise their 2026 EPS outlook and agree to sell HanesBrands Australia.

Earnings Flash (GIL) Gildan Activewear Inc. Reports Q2 Revenue $1.58B, vs. FactSet Est of $1.61B

Gildan Activewear Inc. reported Q2 revenue of $1.58 billion, falling short of the FactSet estimate of $1.61 billion. However, the company's fiscal Q2 adjusted earnings and net sales rose, leading them to raise their 2026 EPS outlook. Additionally, Gildan Activewear agreed to sell HanesBrands …

Gildan Reports Strong Second Quarter Results, Updates its Full Year 2026 Guidance and Announces the Sale of HanesBrands Australia

Gildan Activewear (all amounts are in U.S. dollars except where otherwise indicated) (1) Please refer to "Non-GAAP financial measures and related ratios" in this press release Second quarter net sales from continuing operations of $1.58 billion up 72.3% over the prior year. Operating margin …

Sei Investments Co. Acquires 60,111 Shares of Gildan Activewear, Inc. $GIL

Sei Investments Co. increased its stake in Gildan Activewear, Inc. by 25% in the first quarter, purchasing 60,111 additional shares to own a total of 300,633 shares valued at $16.7 million. Other institutional investors also adjusted their holdings, with institutional ownership now at 82.83%. …

Gilead (GILD) Stock Stays Cheap On Its 130% Five Year Run

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences stock has delivered a strong 130.1% return over the past 5 years, which raises a clear question for investors about how much …

Gilead Sciences (GILD) Following Trodelvy Progress And A Fair Value Debate

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Gilead Sciences (GILD) is back in focus after regulators in Europe issued a positive opinion on expanding Trodelvy's use alongside Keytruda for certain …

How Investors May Respond To Gilead Sciences (GILD) EMA Backing Trodelvy Plus Keytruda In First-Line TNBC

The European Medicines Agency's committee has adopted a positive opinion backing Gilead Sciences' Trodelvy in combination with Merck's Keytruda as a first-line treatment for certain adults with advanced triple-negative breast cancer. This recommendation, based on strong Phase 3 data, strengthens Gilead's oncology narrative, with …

Gildan (NYSE: GIL) boosts 2026 guidance, agrees HanesBrands Australia sale

Gildan Activewear reported strong Q2 2026 results with net sales up 72.3% year over year, driven by the HanesBrands acquisition. The company boosted its full-year 2026 guidance, expecting revenue at the low end of $6.0–$6.2 billion and adjusted diluted EPS of $4.65–$4.75. Additionally, Gildan …

Gilead to Report Q2 Earnings: How Should You Play the Stock Now?

Gilead Sciences is set to report its second-quarter earnings on August 4th, with analysts forecasting $7.37 billion in sales and a $7.07 loss per share. While the company's HIV franchise, led by Biktarvy and Yeztugo, continues to drive strong growth and is poised for …

BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.

Off-the-shelf CAR-T therapies are emerging as a potential alternative to autologous treatments, with companies like Caribou Biosciences positioning their drugs to fill market gaps rather than directly compete with established treatments from Gilead and Bristol Myers Squibb. Caribou's vispa-cel, for instance, showed promising progression-free …

GIL INVESTIGATION: Gildan Securities Fraud Investigation into Channel Stuffing Allegations is Ongoing – Contact BFA Law if You Lost Money

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Gildan Activewear Inc. (NYSE:GIL) for potential securities fraud after its significant stock drop. If you invested in Gildan, you are encouraged to obtain …

Gildan Activewear, Inc. $GIL Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC significantly reduced its stake in Gildan Activewear, Inc. (NYSE:GIL) by 72.2% in the first quarter, selling 1,380,968 shares. Despite this, other hedge funds like Cumberland Partners Ltd and Cannell & Spears LLC increased their holdings. Gildan Activewear reported strong Q1 …

Royal Bank of Canada Acquires 1,193,718 Shares of Gildan Activewear, Inc. $GIL

Royal Bank of Canada has increased its stake in Gildan Activewear (NYSE:GIL) by 20.9%, purchasing an additional 1.19 million shares and now owning 3.73% of the company. Other institutional investors like Caisse de depot et placement du Quebec and Vanguard Group Inc. also significantly …

Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Atea Pharmaceuticals Inc. announced on Tuesday positive topline findings from its pivotal North American Phase 3 C-BEYOND clinical trial evaluating its oral antiviral therapy for chronic hepatitis …

Gildan Activewear Inc. Price Target Is Maintained at C$108.00/Share by Desjardins Securities

Desjardins Securities has maintained its price target for Gildan Activewear Inc. at C$108.00 per share. This indicates the firm's continued assessment of the company's valuation.

Gilead Sciences, Inc. Revenue Breakdown – BIVA:GILD

This article provides a revenue breakdown for Gilead Sciences, Inc. (BIVA:GILD), highlighting its top-performing segment and key regional contributions. Last year, the company generated 530.79 billion MXN, with the Human Immunodeficiency Virus segment accounting for 374.11 billion MXN and the United States being the …

Gilead Sciences (GILD) Laps the Stock Market: Here's Why

Gilead Sciences (GILD) recently outperformed the stock market, closing up 2.91% while the S&P 500 gained only 0.21%. Over the past month, the stock has climbed 3.32%, surpassing the Medical sector's loss. The company is set to report earnings on August 4, 2026, with …

Is Gilead Sciences (GILD) Overvalued Following Its Trodelvy Europe Expansion Win?

Gilead Sciences (GILD) is under scrutiny after the European Medicines Agency's committee backed the use of its drug Trodelvy for certain breast cancer patients. Despite strong share price performance over the past year, the company's valuation is debated, with one narrative suggesting it's 1.7% …